BDTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Black Diamond Therapeutics Inc (BDTX) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available. The stock's technical indicators are weak, financial performance is deteriorating, and there are no significant positive catalysts or trading signals to support an immediate buy decision. Holding off on investment is recommended until stronger signals or catalysts emerge.
The stock is showing a negative trend with a significant regular market price drop of -16.67%. The MACD is negative and expanding, RSI is at 28.179 (neutral but close to oversold), and moving averages are converging, indicating no clear upward momentum. Support levels are close to the current price, with S1 at 2.141 and S2 at 2.002, suggesting potential further downside risk.
NULL identified. No recent news or significant insider/hedge fund activity. Analyst maintains an Overweight rating but has lowered the price target from $9 to $8, indicating reduced confidence.
The stock has experienced a sharp drop in price (-16.67% regular market change). Financial performance is weak, with a significant drop in net income (-45.38% YoY) and EPS (-46.43% YoY). No recent congress trading data or influential figure activity to support the stock.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -$8.498M (-45.38% YoY), and a decline in EPS to -0.15 (-46.43% YoY). Gross margin remains at 100%, but the overall financial health appears weak.
Piper Sandler analyst Kelsey Goodwin maintains an Overweight rating but has lowered the price target from $9 to $8, reflecting reduced optimism. No other recent analyst updates or upgrades.
